ergoline and Cerebrovascular-Disorders

Topics: Adult; Aged; Brain; Cerebrovascular Disorders; Dopamine; Drug Evaluation; Ergolines; Humans; Kinetics; Lisuride; Middle Aged; Receptors, Dopamine; Receptors, Serotonin; Serotonin

Topics: Aged; Amantadine; Animals; Brain; Cats; Cerebrovascular Circulation; Cerebrovascular Disorders; Clinical Trials as Topic; Ergolines; gamma-Aminobutyric Acid; Humans; Lisuride; Memory Disorders; Mice; Pantothenic Acid

Topics: Administration, Oral; Adult; Aged; Cerebrovascular Circulation; Cerebrovascular Disorders; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Humans; Infusions, Intravenous; Middle Aged; Nicergoline; Pentoxifylline; Theobromine; Vinca Alkaloids

28 persons with an average age of 55 years were treated for 180 days with daily doses of 30 mg nicergoline (Sermion) and 28 persons of a comparable age were treated for the same length of time with 6 mg dihydroergotamine mesilate (DHETM) daily. Unwanted reactions occurred to a small degree in both treatment groups; they were mostly of a temporary nature and did not impede continuation of treatment. The results of the psychometric tests showed an increase in performance in both groups which was partly caused by the learning effect in repeated tests. The answers given by the patients concerning subjective changes in symptoms and general condition showed no significant differences between the two treatment groups. This leads to the assumption that both compounds have a similar effect. The analyses of the EEG activities showed a characteristic increase in the fast EEG activities after the application of nicergoline. This would indicate that there are differences in the pharmacodynamics in comparison with DHETM.

Topics: Aged; Amnesia; Cerebrovascular Disorders; Clinical Trials as Topic; Dihydroergotamine; Double-Blind Method; Electroencephalography; Ergolines; Female; Humans; Male; Middle Aged; Nicergoline; Psychometrics; Psychomotor Performance; Random Allocation

Topics: Aged; Amantadine; Animals; Brain; Cats; Cerebrovascular Circulation; Cerebrovascular Disorders; Clinical Trials as Topic; Ergolines; gamma-Aminobutyric Acid; Humans; Lisuride; Memory Disorders; Mice; Pantothenic Acid

A double-blind study was carried out on 56 geronto-psychiatric in-patients who suffered from cerebral metabolic and nutritional disturbances to prove the effectiveness of 10-methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate (nicergoline, Sermion). After a washout-phase of eight days the patients in the verum group received 3 x 1 dragée at 10 mg for a period of 12 weeks. For methodical reasons only patients with slight transit syndromes and, of these, only the first four weeks of examination were included in the present analysis. Thus 8 verum and 9 placebo patients remain whose findings during the trial are recorded in three procedures of capacity and two procedures of self-assessment (syndrome short test, repeating figures and letters, reading letters; scale for general somatic discomfort, scale for vegetative functional disturbances). In the measuring procedures there is a tendency towards improvement under the treatment with nicergline compared with placebo during the first three weeks. But the present results are not sufficient to come to a clear decision on the effectiveness of nicergoline in patients with cerebrovascular insufficiency.

Topics: Aged; Cerebrovascular Disorders; Clinical Trials as Topic; Ergolines; Humans; Nicergoline; Placebos

An examination was carried out on the efficacy of 10-methoxy-1,6-diemethyl-ergoline-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) on the symptoms of functional side effects of arterial hypertension and chronic circulatory insufficiency as regards the psychomotoric activity and the relational activity; 359 patients suffering from crebrovascular insufficiency were included in the study. The compound was applied in a daily dose of 10 mg i. m. for 5 days and then in a daily dose of 15 mg orally for 1 month. In the entire symptom complex of cerebro-vascular insufficiency a positive effect of nicergoline could be observed; the results of all clinical criteria and their therapeutic relevance are discussed.

Topics: Adult; Aged; Cerebrovascular Disorders; Chronic Disease; Clinical Trials as Topic; Ergolines; Female; Humans; Hypertension; Male; Middle Aged; Nicergoline

A double-blind clinical trial of vincamine hydrochloride and a known dihydrogenated ergotoxine derivative, administered i.m. for 10 days, was conducted on 2 groups of 10 hospitalised cerebrovascular patients. Hemiplegia was evaluated prior to treatment and on its 5th and 10th day, by a scoring system. Statistical assessment of the results and the clinical observations showed that vincamine hydrochloride can be usefully employed in the treatment of acute cerebrovascular accidents on account of its marked effectiveness and rapid action--these being attributable to its cerebral vasoregulatory and metabolic mechanism, and to increased availability due to salification of the basic molecule--, coupled with its excellent local and general tolerability.

Topics: Aged; Cerebrovascular Disorders; Clinical Trials as Topic; Drug Evaluation; Ergolines; Female; Humans; Male; Middle Aged; Vinca Alkaloids; Vincamine

Topics: Adrenergic alpha-Antagonists; Brain; Cerebrovascular Circulation; Cerebrovascular Disorders; Clinical Trials as Topic; Drug Evaluation; Ergolines; Humans; Nicotinic Acids; Regional Blood Flow

Topics: Aged; Cerebrovascular Disorders; Clinical Trials as Topic; Drug Evaluation; Ergolines; Female; Humans; Male; Middle Aged; Nicotinic Acids; Platelet Adhesiveness; Vasodilator Agents

Topics: Adult; Aged; Bromine; Cerebrovascular Disorders; Clinical Trials as Topic; Drug Tolerance; Ergolines; Evaluation Studies as Topic; Female; Humans; Male; Middle Aged; Nicotinic Acids

Topics: Age Factors; Aged; Cerebrovascular Circulation; Cerebrovascular Disorders; Clinical Trials as Topic; Dementia; Ergolines; Female; Humans; Male; Neurologic Examination; Projective Techniques; Psychological Tests; Vasodilator Agents

Combined clinicophysiological investigation was performed in IDE (195 patients) in order to assess the degree of cerebral circulation disorders and their impact on the levels of brain functional activity. The informative values of several quantitative indices of brain hemodynamics and neurodynamics were assessed with respect to the patients' age. Single administration and full course of cavinton and sermion (nicergoline) were effective as judged by cerebral circulation studies (133Xe clearance), brain bioelectric activity (EEG frequency integration analysis, visual evoked potentials). In senile patients, the effect of i.v. sermion administration was dose-dependent.

Topics: Aged; Cerebrovascular Circulation; Cerebrovascular Disorders; Ergolines; Humans; Middle Aged; Nicergoline; Time Factors; Vasodilator Agents; Vinca Alkaloids

The effects of a new eburnamenine derivative (3 beta,14 alpha, 16 alpha)-(+/-)-14,15-dihydro-20,21-dinoreburnamenin-14-ol (vindeburnol, RU 24722) on EEG, on brain energy metabolism and on local cerebral blood flow (LCBF) and in different experimental models of cerebral insufficiency were compared with those of vincamine, vinburnine (1-eburnamonine), dihydroergotoxine mesilate and nicergoline. Vindeburnol at 2 mg/kg i.v., increased the EEG resistance time in rats subjected to asphyxia anoxia and at 10 mg/kg s.c., significantly improved the electrocortical recovery of gerbils subjected to a 10-min cerebral ischemia. Vindeburnol (10 mg/kg i.p.) significantly retarded glucose, phosphocreatine and adenosine triphosphate utilization and lactate production in mouse brain during 10 s of decapitation ischemia. The cerebral metabolic rate was 10.34 mmol/kg/min, which was about 50% of the control value. At 10 mg/kg i.p., the product induced a slight and transient increase in LCBF. Vincamine improved the early phase of the postischemic electrocortical recovery in the gerbil, had no effect on cerebral energy substrates and slightly increased the LCBF for 15 min. Dihydroergotoxine mesilate improved the early phase of the electrocortical recovery in gerbils subjected to ischemia, did not significantly modify the energy substrates and rapidly increased the LCBF, which was normal after 30 min. Vinburnine and nicergoline were inactive in the cerebral insufficiency models used and did not significantly modify cerebral energy metabolism. These results show that vindeburnol has a different pharmacological profile from vincamine, vinburnine, dihydroergotoxine mesilate and nicergoline, and suggest that vindeburnol may be therapeutically effective in cerebral insufficiency.

Topics: Animals; Brain Ischemia; Cerebral Cortex; Cerebrovascular Circulation; Cerebrovascular Disorders; Dihydroergotoxine; Electroencephalography; Ergolines; Gerbillinae; Male; Mice; Mice, Inbred Strains; Nicergoline; Rats; Rats, Inbred Strains; Vinca Alkaloids; Vincamine

The effect of the alpha-adrenoblockers, nicergoline (N) and dihydroergotoxin (DHET), on the cerebral vessels and the systemic hemodynamics was studied in 152 patients with acute and chronic vascular diseases of the brain. It was established that the hypotensive action of alpha-blockers was the greater the higher was the initial arterial hypertension. REG conducted during an hour after the intravenous administration of N and DHET revealed an increase in the pulse blood filling and an improvement of the arterial tone. Changes in vascular resistance were heterogeneous. Both drugs induced the venous outflow but there were no signs of venous hypotension. An improvement in the systemic and cerebral hemodynamics correlated with clinical improvement.

Topics: Blood Pressure; Brain Ischemia; Cerebrovascular Circulation; Cerebrovascular Disorders; Dihydroergotoxine; Ergolines; Humans; Nicergoline; Plethysmography, Impedance; Subarachnoid Hemorrhage; Vascular Resistance

The possible alteration of central dopaminergic (DA) function, which accompanies the development and persistence of hypertension, was studied in SHRSP by measuring the lisuride-induced locomotor activity and the swimming ability. 1) When administered at a dosage of 50 micrograms/kg, lisuride, a DA agonist, induced significant increases of the locomotor activity in one- and 2-month-old Wistar Kyoto rats (WKY), but not in the 6 month-old rat. Differing from the response of WKY, SHRSP showed only a moderate increase in the locomotor activity at the age of one month (means of systolic blood pressure: 128 mmHg) and apparently no increase at the age of 2 months (176 mmHg). In 6 month-old SHRSP (238 mmHg), hypomotility but not hypermotility was induced by the lisuride administration. 2) Though no significant difference was detected at the age of 4 months, the swimming ability of SHRSP at the age of 8 months was deteriorated significantly as compared to that of WKY, and the impaired swimming performance of SHRSP was improved by the administration of lisuride. These results indicate that some alterations in the synaptic sites of the central DA neuron occurred already at an early stage of the hypertensive development, followed under persistent hypertension by the progressive deterioration of the motor-coordination ability as detected in the swimming ability.

Topics: Age Factors; Animals; Cerebrovascular Disorders; Ergolines; Hypertension; Lisuride; Locomotion; Male; Rats; Rats, Inbred Strains; Receptors, Dopamine; Swimming

Eight month-old SHRSP were treated s.c. with lisuride (50 micrograms/kg per day) for 5 weeks to examine the effect of the central dopaminergic agonist on the deterioration of swimming ability that occurred and progressed under persistent hypertension. General observations on signs and symptoms and histopathological examinations were also carried out with the same rats to evaluate the drug effect on the deterioration of hypertensive symptoms. The poor swimming performance of hypertensive SHRSP was improved significantly by the direct action of lisuride with a maximal effect at the 2nd week of the treatment, although the progress of the deterioration itself was not prevented by the chronic treatment. One week after the drug treatment, 2 out of 8 rats in the control group but none in the lisuride-treated group exhibited the abnormal behavior with aggressiveness, a typical sign of the occurrence of cerebrovascular lesions. Furthermore, macroscopic and histopathological examinations carried out 2 weeks after the drug treatment revealed that severities of the histopathological lesions such as myocardiac necrosis and arteriolosclerosis in the kidney, adrenal and testis were significantly lower in the lisuride-treated group than in the control.

Topics: Adrenal Glands; Animals; Behavior, Animal; Cerebrovascular Disorders; Ergolines; Hypertension; Kidney; Lisuride; Male; Myocardium; Rats; Rats, Inbred Strains; Swimming

Topics: Aged; Arteries; Cerebrovascular Disorders; Ergolines; Female; Humans; Hypertension; Leg; Male; Middle Aged; Myocardial Infarction; Nicergoline; Vascular Diseases

Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Apomorphine; Blood Volume; Brain; Bromocriptine; Cats; Cerebrovascular Disorders; Ergolines; Oxygen; Phenoxybenzamine

The results obtained from a group of 36 patients with non-acute cerebral vascular disturbances of various forms were evaluated. The clinical course and additional examinations are reported: electroencephalography, visually evoked potentials and cerebral rheography for the assessment of different cerebral regions and an interhemispherical comparison. The determination of the data obtained by rheography can be applied to the whole patient group. All tests were carried out before treatment and after a period of treatment with 15-20 mg 10-methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) administered daily p.o. On the basis of the therapeutic results conclusions can be drawn as to clinical improvement and EEG normalisation and visually evoked potentials. The changes in the amplitude and the changes in the systolic gradient recorded by the rheogramme as well as the tendency to correction of dyssymmetry can be described as the result of nicergoline on the cerebral vascular system, on the oxygen supply and on the metabolism of the brain tissue.

Topics: Adult; Aged; Cerebrovascular Disorders; Ergolines; Female; Humans; Male; Middle Aged; Nicergoline

Topics: Animals; Cats; Cerebrovascular Circulation; Cerebrovascular Disorders; Ergolines; Microcirculation; Papaverine

Topics: Cerebrovascular Disorders; Drug Evaluation; Ergolines; Face; Hemodynamics; Humans; Nicergoline; Skin Temperature; Thermography

Topics: Adult; Aged; Cerebral Angiography; Cerebrovascular Circulation; Cerebrovascular Disorders; Electrocardiography; Ergolines; Female; Humans; Intracranial Arteriosclerosis; Intracranial Embolism and Thrombosis; Ischemic Attack, Transient; Male; Middle Aged; Vinca Alkaloids

Topics: Adult; Aged; Arteriosclerosis; Blood Pressure; Cerebrovascular Disorders; Ergolines; Evaluation Studies as Topic; Female; Glomerulonephritis; Heart Block; Humans; Hypertension; Intracranial Arteriosclerosis; Intracranial Embolism and Thrombosis; Male; Memory Disorders; Middle Aged; Vascular Diseases; Vascular Headaches; Vision Disorders

Topics: Antihypertensive Agents; Cerebrovascular Disorders; Chronic Disease; Ergolines; Female; Humans; Hypertension; Male

Topics: Aged; Arterial Occlusive Diseases; Cerebrovascular Disorders; Ergolines; Female; Humans; Intracranial Arteriosclerosis; Ischemic Attack, Transient; Leg; Male; Middle Aged; Vasodilator Agents

Topics: Adult; Aged; Cerebrovascular Disorders; Ergolines; Erythrocytes; Female; Giant Cell Arteritis; Headache; Humans; Hypertension; Male; Meningitis; Metabolic Clearance Rate; Middle Aged; Migraine Disorders; Osteoarthritis; Serotonin Antagonists; Sinusitis; Urea; Vascular Headaches

Topics: Analgesics; Cerebrovascular Disorders; Ergolines; Ergotamine; Headache; Humans; Hypertension; Hypnotics and Sedatives; Metabolic Diseases; Methysergide; Migraine Disorders; Psychotherapy; Tranquilizing Agents